DBTECH

Dear Reader, As per your request, you have been removed from our mailing list for ET Mutual Funds Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

VIEW IN BROWSER | SUBSCRIBE THU, OCT 31, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Happy Thursday! New research showing additional health benefits of the weight loss drug Wegovy seems to crop up every week.  This time around, Novo Nordisk's blockbuster treatment helped reduce knee pain in patients with a type of arthritis and obesity, according to research published Wednesday in the New England Journal of Medicine. The study was funded by Novo Nordisk, which is conducting several studies on the other potential treatment uses of semaglutide, the active ingredient in Wegovy. The results of the 68-week trial could be a big deal for the Danish drugmaker: It could pave the way for regulatory approval of semaglutide for osteoarthritis, a degenerative joint disease that causes the cartilage and bone in your joints to break down over time.  It would be yet another expansion of the accepted us